Kazia Therapeutics CEO Dr. John Friend discussed how paxalisib is being studied in HR-positive, HER2-negative breast cancer, why researchers are focusing on treatment resistance and what the ongoing clinical trial could show for patients.
Dr. John Friend
Advertisement
Articles by Dr. John Friend
Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.
The investigational drug, first developed for brain cancer, is being tested to see whether it can make resistant tumors respond to treatment again.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Exercise Gave Me Control. It Didn’t Cure My Cancer
2
Living With Incurable Cancer: The Emotional Toll of Never Knowing What Comes Next
3
A Light-Based Treatment Is Now FDA Approved for a Common Skin Cancer
4
Endoscopic Nipple-Sparing Mastectomy: What Breast Cancer Patients Should Know
5